Programme highlights: EU project sessions at Congress - ERS

EU project sessions at Congress

ERS and the European Lung Foundation (ELF) collaborate on a number of EU-funded projects that look at unmet medical and societal needs in the respiratory field. The projects address different aspects in the translational process and how observations in the clinic, laboratory or community turns into interventions that improve the health of individuals and the public.

At this year's Congress in Amsterdam, there are three sessions on EU projects that ERS and ELF are involved in. Read more about the sessions below.

The European progress on finding SOLACE in lung cancer screening

27 September | 14:05-14:50 CEST

This session aims to provide an update on the most recent progress of SOLACE which is a pioneering EU4Health project under Europe’s Beating Cancer Plan. At the end of this session the participants will: 1. obtain an update on the three on-going SOLACE implementation pilots in eleven EU Member States, and 2. learn about the progress made in the SOLACE Lung Cancer Screening guideline, implementation and quality assurance package as well as the related SOLACE Tool box approach project.

Learn more and view in the Congress programme.

Learn more about SOLACE.

Advancing lung cancer care with real-world evidence, AI and computerized clinical guidelines

28 September | 9:00-9:45 CEST

The aims of this session is to introduce the OPTIMA IMI project and its input to the lung cancer research field. We will showcase our developments, including the recent lung cancer research questions we are tackling, and the real-world evidence and AI analytics platform we have developed and its application to lung cancer research. We will also present our guidelines-based decision support tool and explore the opportunities for users outside of the project to join the effort and participate in these advancements.

Learn more and view in the Congress programme.

Learn more about OPTIMA.

Identification of novel immunological treatment targets in severe asthma

30 September | 15:15-16:00 CEST

3TR aims to provide fundamental new insights into the mechanisms of response and non-response to treatment. Thereby, the consortium challenge the conventional “single disease”-based approach, in which diseases are classified according to their end-organ involvement rather than the molecular pathways underpinning them. Consequently, they propose a paradigm shift in the way we look at diseases: Promoting a scientific evidence-based rationale for treatment selection, rather than following the traditional trial and error approach, 3TR will have significant implications for future patient management and the assessment of efficacy, safety and quality of future health products.

Learn more and view in the Congress programme.

Learn more about 3TR.